Previous Article | Next Article 
Journal of Virology, September 2000, p. 7834-7841, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Involvement of the Zinc-Binding Capacity of Sendai
Virus V Protein in Viral Pathogenesis
Cheng
Huang,1
Katsuhiro
Kiyotani,1
Yutaka
Fujii,1
Noriko
Fukuhara,1
Atsushi
Kato,2,
Yoshiyuki
Nagai,2,
Tetsuya
Yoshida,1 and
Takemasa
Sakaguchi1,*
Department of Bacteriology, Hiroshima
University School of Medicine, Hiroshima
734-8551,1 and Department of Viral
Infection, Institute of Medical Science, University of Tokyo, Tokyo
108-8639,2 Japan
Received 1 March 2000/Accepted 30 May 2000
 |
ABSTRACT |
The V protein of Sendai virus (SeV) is nonessential to virus
replication in cell culture but indispensable to viral pathogenicity in
mice. The highly conserved cysteine-rich zinc finger-like domain in its
carboxyl terminus is believed to be responsible for this viral
pathogenicity. In the present study, we showed that the cysteine-rich
domain of the SeV V protein could actually bind zinc by using
glutathione-S-transferase fusion proteins. When the seven
conserved cysteine residues at positions 337, 341, 353, 355, 358, 362, and 365 were replaced individually, the zinc-binding capacities of the
mutant proteins were greatly impaired, ranging from 22 to 68% of that
of the wild type. We then recovered two mutant SeVs from cDNA, which
have V-C341S and V-C365R mutations and
represent maximal and minimal zinc-binding capacities among the
corresponding mutant fusion proteins, respectively. The mutant viruses
showed viral protein synthesis and growth patterns similar to those of
wild-type SeV in cultured cells. However, the mutant viruses were
strongly attenuated in mice in a way similar to that of SeV
V
C, which has a truncated V protein lacking the
cysteine-rich domain, by exhibiting earlier viral clearance from the
mouse lung and less virulence to mice. We therefore conclude that the
zinc-binding capacity of the V protein is involved in viral pathogenesis.
 |
INTRODUCTION |
Sendai virus (SeV), which
belongs to the genus Respirovirus in the family
Paramyxoviridae, is a respiratory tract pathogen of rodents.
Like other members within the order Mononegavirales, it is
an enveloped virus with a single-stranded, negative-sense RNA genome of
approximately 15.4 kb. The arrangement of the SeV genome starts with a
short 3' leader sequence, followed by six genes encoding the structural
proteins, including N (nucleocapsid), P (phosphoprotein), M (matrix), F
(fusion), HN (hemagglutinin-neuraminidase), and L (large) proteins and
terminates with a 5' trailer sequence (19).
Among the six genes, the P gene was found to be unique in that it
encodes not a single but multiple proteins. The colinear transcript
encodes the P protein as well as the C, C', Y1, and Y2 proteins; these four proteins are translated in a
shifted frame by alternative translational starts. The P gene also
directs synthesis of an accessory mRNA for the V protein by inserting a
pseudotemplated G residue at the specific editing site (30,
31). Consequently, the V and P proteins have the same 317 residues at the amino terminus (the P/V common region), while the V
protein contains a 67-residue unique carboxyl terminus (the Vu region).
This Vu region features a motif formed by seven cysteine residues
(CX3CX11CXCX2CX3CX2C, where X refers to any amino acid residue), which are highly
conserved in almost all the members of the subfamily
Paramyxovirinae. The number and spacing of these cysteine
residues resemble those of zinc finger structures and metalloproteins,
and the V proteins of other members of the subfamily
Paramyxovirinae, including simian virus 5 (SV5), measles
virus, and Newcastle disease virus, have been shown to bind zinc
(21, 25, 29). It is not known, however, whether the SeV V
protein actually binds zinc ions. Furthermore, the biological
significance of the zinc binding is unknown.
The proteins encoded by the P gene vary in their role in virus
replication. By complexing with the L protein or forming a homotrimer,
the P protein is involved in virus mRNA transcription and genome
replication (4, 7, 13). It also binds soluble N protein,
perhaps acting as a chaperone to mediate nucleocapsid formation
(6, 13). In contrast to the well-characterized P protein,
little is known about the functions of the C and V proteins. The C
proteins have been shown to be indispensable for efficient virus
multiplication and pathogenicity (18), and they have also
been shown to block interferon-mediated antivirus responses (11,
12). The SeV V protein is reportedly able to suppress virus
genome RNA replication in vitro with a defective interfering minigenome
model (5). However, the exact function of the V protein in
virus replication and pathogenicity is not clear so far. Recent studies
using a reverse genetics system have provided insights into the role of
the V protein in virus infection in mice (8, 9, 14,
15; reviewed in references 23 and 24). The V-deficient virus [V(
)] and the
Vu-deficient virus (V
C) both replicate as efficiently as
the wild-type parent SeV in cell culture with no significant
alterations in viral mRNA transcription, genome replication, or protein
synthesis. In contrast, both the V(
) and V
C viruses
are remarkably attenuated in mice, indicating an imperative role for
the V protein, predominantly the Vu domain, in SeV pathogenicity in
vivo. It has been demonstrated that the V protein is necessary for a
virus to maintain a high viral load in the mouse lung as well as to
inhibit host innate immunity in the early stage of infection.
In the present study, we first proved that the Vu domain of the SeV V
protein is capable of binding zinc atoms with its highly conserved
cysteine residues. We further investigated the effect of
cysteine-dependent zinc binding on viral pathogenicity in mice by
generating V mutant SeVs.
 |
MATERIALS AND METHODS |
Cells, viruses, and antibodies.
LLC-MK2 cells
were grown in Eagle's minimal essential medium (MEM) supplemented with
10% fetal calf serum. The wild-type SeV (SeV WT) was derived from cDNA
of the Z strain, and its mutants were propagated in embryonated chicken
eggs. Infectivity was measured by an immunofluorescent infectious focus
assay (17) and expressed as cell infectious units (CIU)/ml.
Hemagglutinating units (HAU) were measured by the standard method using
a microtiter plate. An anti-SeV antibody was prepared by immunizing
rabbits with purified SeV virions, and antibodies against P, C, and Vu
were prepared with histidine-tagged P, C, and Vu proteins,
respectively, purified from Escherichia coli
(14).
Gene cloning, expression, and purification of the SeV V, P/V
common, and Vu proteins.
DNA manipulations were performed
basically according to a manual (1). SeV V, P/V common, and
Vu DNA fragments were prepared from the plasmid pIRES-V, harboring SeV
V cDNA, with the Expand High Fidelity PCR system (Boehringer Mannheim,
Indianapolis, Ind.). Primers used for V gene amplification were P/V-5
(5'-ATGGCGGATCCGAGCTCAGCATGGATCAAGATGC-3') and Vstop
(5'-ACCTTCTCGAGCCTTACGAGCGGAAGATTC-3'). For the P/V common
gene, the primers used were P/V-5 and P/V stop
(5'-ACCTTCTCGAGCCTTAGCCCTTTTTGTTGAGTC-3'). For the V
unique gene, the primers used were Vu-5
(5'-ATGGCGGATCCGAGCTCACCATGCATAGGAGAGAACAC-3') and Vstop. The PCR
products were inserted into a glutathione-S-transferase (GST) fusion expression vector, pGEX-4T-1 (Amersham Pharmacia Biotech,
Piscataway, N.J.), between the BamHI and XhoI
sites. The constructs were then introduced into E. coli DH1
competent cells. The recombinant clones were confirmed by sequence
analysis using a 310 genetic analyzer (PE Biosystems, Foster City,
Calif.).
GST fusion proteins were expressed and purified according to the
manufacturer's manual. Briefly, recombinant protein expression in BL21
cells was induced, and the cells were collected by centrifugation and
disrupted by mild sonication. After centrifugation, supernatants were
directly applied to a glutathione-Sepharose 4B affinity chromatography column and eluted with glutathione. Protein was quantified using the
Bradford protein assay.
Protein analysis by Western blotting.
Western blotting was
performed as described previously (28). Briefly, proteins
were separated on sodium dodecyl sulfate-15% polyacrylamide gel
electrophoresis (SDS-15% PAGE) and transferred onto a polyvinylidene
difluoride membrane (Millipore, Bedford, Mass.) using a semidry protein
transfer apparatus (Sartoblot II-S; Sartorius, Edgewood, N.Y.). The
blotted membranes were treated with rabbit anti-SeV serum or anti-Vu
serum (diluted to 1:500) and subsequently with horseradish
peroxidase-conjugated mouse anti-rabbit immunoglobulin G antibody
(Organon Technika Cappel; 1:1,000). Reactive proteins were visualized
in a visualization buffer (0.5 mg of 3,3'-diaminobenzidine per ml,
1.4% H2O2, 50 mM Tris-HCl [pH 7.5]).
Mutagenesis of the Vu gene.
A 0.8-kb SmaI
fragment from SeV cDNA plasmid pSeV(+), corresponding to nucleotides
2764 to 3556 in the SeV antigenomic cDNA, was subcloned into plasmid
pGEM-3 (Promega, Madison, Wis.). Site-directed mutagenesis was
performed on double-stranded plasmid using the U.S.E. mutagenesis kit
(Amersham Pharmacia Biotech). All of the mutants were screened by
sequence analysis. The mutated Vu genes were further amplified by PCR
and inserted into the expression vector pGEX-4T-1.
Zinc-binding assay.
Samples were separated by SDS-15% PAGE
and electroblotted onto membranes as described above. The zinc-binding
assay was performed on the blotted membrane using
65ZnCl2 (Amersham Pharmacia Biotech) as
described previously (2). Membranes were equilibrated in
renaturing buffer (100 mM Tris-HCl [pH 6.8], 50 mM NaCl, 10 mM
dithiothreitol [DTT]) for 1 h with three changes of the buffer,
then rinsed in labeling buffer (100 mM Tris-HCl [pH 6.8], 50 mM NaCl)
twice, and incubated with 10 µM 65ZnCl2 in
labeling buffer for 15 min. The labeling buffer was flushed with
nitrogen gas to remove dissolved oxygen before use. The membranes were
further rinsed in wash buffer (100 mM Tris-HCl [pH 6.8], 50 mM NaCl,
1 mM DTT) twice, then washed for 1 h with three changes of the
buffer, and subjected to autoradiography with a Fujix BAS 2000 image
analyzer (Fuji, Tokyo, Japan). Transferred proteins were further
stained with amido black 10B, and they were quantified by densitometry
using MacBAS software (Fuji).
Recovery of SeV from cDNA.
The 0.8-kb SmaI
fragments (2764 to 3556) after mutagenesis were subcloned into a
plasmid possessing the
EcoRI2871-BamHI5011
fragment by using the two SmaI sites in the fragment and the vector, and the EcoRI-BamHI fragments were
subsequently transferred into the ClaI fragment
corresponding to nucleotides 2090 to 5335. The ClaI
fragments were finally transferred to pSeV(+) plasmid to generate
pSeV(+)-V-C341S and pSeV(+)-V-C365R. These
steps were similar to those described before (26), and SeV
was recovered from the recombinant plasmids as described previously
(16).
Protein analysis by metabolic labeling and
immunoprecipitation.
Confluent monolayers of LLC-MK2
cells in a 3.5-cm dish were infected with SeV at a multiplicity of
infection (MOI) of 20. After 7 h, the cells were labeled with
35S-labeled cysteine-methionine
([35S]Pro-mix; 3.7 MBq/ml; Amersham Pharmacia Biotech)
for 30 min in methionine- and cysteine-free Dulbecco's modified MEM.
The cells were lysed in radioimmunoprecipitation assay buffer (10 mM
Tris-HCl [pH 7.4], 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 150 mM NaCl). Polypeptides were immunoprecipitated with anti-SeV,
anti-Vu, or anti-C serum and analyzed by SDS-PAGE as described
previously (27). An autoradiogram was analyzed by using an
image analyzer.
Animal experiments.
Specific-pathogen-free, 3-week-old male
mice of the ICR/Crj (CD-1) strain, purchased from Charles River Japan,
Inc. (Atsugi, Japan), were intranasally inoculated with
106, 107, or 108 CIU of virus
inoculum per mouse under mild anesthesia with ether, and their body
weights and clinical symptoms were checked daily. In an experiment for
virus replication, the mice were sacrificed and virus infectivity in
the lung was measured at certain time intervals. All of the mice were
kept in a bioclean condition in the facility for animal experiments of
the Hiroshima University School of Medicine.
 |
RESULTS |
Expression of SeV V, P/V common, and Vu proteins in E. coli.
To determine whether the SeV V protein can bind zinc ion,
the V-related polypeptides were expressed in E. coli. The V,
P/V common, and V unique genes were cloned into the pGEX-4T-1
expression vector to generate GST fusion proteins (Fig.
1). SDS-PAGE and Western blot assay
results (Fig. 2A) confirmed the
expression of GST-V, GST-P/V common (P/Vcom), and GST-Vu proteins.
GST-V and GST-P/Vcom were reactive to rabbit anti-SeV serum raised
against purified virions, while GST-Vu was not. This observation is
consistent with the observation that the V protein is not a structural
protein in SeV virions (5). Anti-Vu serum, raised against
the purified Vu peptide expressed in E. coli, reacted with
both GST-V and GST-Vu proteins but not with the GST-P/Vcom protein.
These results show the authenticity of the fusion proteins.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of GST fusion proteins. SeV V,
P/Vcom, and Vu peptides were fused to the carboxyl terminus of GST. The
amino acid residue numbers of the V protein are indicated.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Western blotting to detect GST fusion proteins.
Expression of GST-V, GST-P/Vcom, and GST-Vu proteins as well as GST was
induced in E. coli, and the proteins were purified by
glutathione-Sepharose 4B affinity chromatography. The proteins were
analyzed by SDS-PAGE and transferred to a membrane. The blots were
stained with anti-SeV antibody ( SeV) or anti-Vu antibody ( Vu) as
a primary antibody, as described in Materials and Methods. Sizes are
shown in kilodaltons. (B) Zinc-binding assay of GST fusion proteins.
The blot was probed with 65ZnCl2 in reducing
conditions to detect zinc binding and processed for autoradiography
(65Zn2+ binding). The same membrane was then
stained with amido black 10B to detect blotted proteins.
|
|
Zinc-binding assay for the GST-V, GST-P/Vcom, and GST-Vu
proteins.
The GST fusion proteins were processed for the
zinc-binding assay. Partially purified GST-V, GST-P/Vcom, and GST-Vu
proteins were resolved by SDS-PAGE and subsequently transferred to a
membrane. The membrane was then incubated with
65ZnCl2 (Fig. 2B). After autoradiography, the
blotted membrane was further stained with amido black 10B (Fig. 2B),
and protein density was measured. Zinc-binding activity determined by
this assay was corrected for the amounts of blotted protein and its
molecular size.
It was found that although GST itself bound
65Zn
2+ to some extent, GST-Vu bound 7.2-fold
more zinc than did GST, exhibiting its
potential zinc-binding capacity.
As predicted, GST-P/Vcom did
not bind zinc, but unexpectedly, neither
did GST-V (Fig.
2B).
This is probably because GST-V might be in a
denatured form unfavorable
to zinc binding after purification from
E. coli or because GST
coupling at the N terminus of the V
protein might interfere with
the binding of zinc ions. However, it is
evident that the highly
conserved, cysteine-rich unique domain at the
carboxyl terminus
of the V protein is capable of coupling zinc
ions.
Mutagenesis of a Vu gene segment.
To investigate involvement
of the conserved cysteine residues in zinc binding, the seven cysteine
residues in the zinc finger-like motif were individually mutated by
site-specific mutagenesis. Mutations were designed so as not to
introduce a mutation into the overlapping P coding frame, because the
same mutations were to be introduced into virus in a later experiment.
The mutations were Cys337
Ser (C337S),
C341S, C353R, C355R,
C358S, C362S, and C365R (Fig.
3). Mutated Vu genes were then inserted
in frame into pGEX-4T-1 to construct a recombinant expression vector.
Purified mutant GST-Vu fusion proteins were analyzed by SDS-PAGE and
transferred to a membrane (Fig. 4A). It
was observed the C362S mutant GST-Vu protein was not
expressed in E. coli, probably due to degradation by a host
protease (data not shown). For the other GST-Vu proteins, an
intermediate band between the full-sized GST-Vu protein and the GST
protein appeared (* in Fig. 4A). This was thought to be because the
mutant proteins acquired partial susceptibility to a protease in
E. coli, probably due to a conformational change by a single
point mutation. If this is in fact the case, since mutations at
different positions generated a similar band, changes in each cysteine
residue may lead to a common conformation. Another intermediate band
appeared in the C355R mutant (Fig. 4A), suggesting that the
mutation may have given rise to another protein conformation.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
Schematic representation of mutant GST-Vu proteins. The
seven cysteine residues conserved among the subfamily
Paramyxovirinae (shaded) were individually replaced with
serine or arginine. Mutations were designed to change a cysteine and,
at the same time, not to change an amino acid of the overlapping P
coding frame for later reverse genetics experiments.
|
|

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
Western blotting of the mutant GST-Vu proteins and their
zinc-binding capacities. Expression of the mutant GST-Vu proteins as
well as GST was induced in E. coli, and the proteins were
purified by glutathione-Sepharose 4B affinity chromatography. The
purified proteins and carbonic anhydrase (CA) were analyzed by SDS-PAGE
and transferred to a membrane. The blot was probed with
65ZnCl2 in reducing conditions to detect zinc
binding and processed for autoradiography (B,
65Zn2+-binding). The same membrane was then
stained with amido black 10B to detect blotted proteins (A). An
asterisk indicates partially degraded GST-Vu proteins. The relative
ratio of zinc binding by the GST-Vu mutants to that of the wild type
was then calculated from data from three independent experiments (C).
Bars indicate standard deviations.
|
|
Zinc-binding assay of mutant Vu proteins.
Purified mutant
GST-Vu proteins were tested for their zinc-binding activity (Fig. 4B).
We quantified zinc binding to full-sized GST-Vu bands with correction
for the amounts of blotted proteins. GST-Vu did not bind zinc ions when
DTT was not included in the binding assay buffer (data not shown).
Thus, zinc-binding experiments must be performed in reducing conditions
for GST-Vu to maintain zinc-binding ability, suggesting that this
coordination is cysteine-mediated in nature. This is also consistent
with the case for papillomavirus E6 and E7 proteins (2). We
included carbonic anhydrase, which binds zinc through three histidine
residues, in this analysis (Fig. 4B). In reducing conditions, however,
carbonic anhydrase did not bind zinc ions strongly.
The results from three independent experiments (Fig.
4C) clearly showed
that the zinc-binding capacity was substantially impaired
by
substitution of the conserved cysteine residues. Cys
365
appeared
to be most essential to the zinc-binding capacity of Vu
protein,
since the C
365R mutation caused a remarkable loss
of binding capacity,
down to only 22% of that of the wild type.
Mutations C
337S and
C
341S led to a relatively
mild reduction in binding capacity,
52 and 68% of wild type,
respectively. For mutations C
353R, C
355R,
and
C
358S, the zinc-binding capacities were 34, 36, and 43% of
wild type, respectively. These results indicate that the zinc-binding
capacity of the V protein is a function of the unique domain in
its
carboxyl terminus and clearly cysteine
dependent.
Generation of SeV with mutations at the cysteine residues of the Vu
motif.
To investigate the effect of the cysteine mutations on
viral pathogenicity, we created two viruses possessing the mutations C341S and C365R, which correspond to the
highest and lowest zinc-binding capacities, respectively, among the
GST-Vu mutants examined. Mutated DNA fragments were introduced into the
whole SeV genomic cDNA, and virus was recovered from the constructs.
The viruses were designated SeV V-C341S and SeV
V-C365R. Virus recovery rate and infectivity in embryonated
eggs were equivalent to those of the wild-type virus (data not shown).
These results of reverse transcription-PCR and nucleotide sequencing
confirmed the introduced mutations in the recovered viruses.
Viral protein synthesis was then investigated. LLC-MK
2
cells were infected with the SeV mutants and metabolically labeled
with
35S-labeled cysteine-methionine. We included the
V-deficient virus,
which has a mutation at the V editing site [SeV
V(

)] (
14),
and a virus with a truncated V protein lacking
the Vu domain because
of a stop codon introduced just after the V
editing site (SeV
V
C) (
15).
Immunoprecipitation with antiserum against SeV
virions revealed that
major viral proteins were similarly synthesized
among all the viruses
investigated (Fig.
5). Anti-C antibody
precipitated
equivalent amounts of C-related polypeptides C' and C and
a faster-migrating
band probably corresponding to Y
1 or
Y
2 (Fig.
5).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
Protein synthesis of SeV V mutants in cultured cells.
SeV V-Cys mutants V-C341S and V-C365R as well
as SeV WT, V( ), and V C were used to infect
LLC-MK2 cells at an MOI of 20. Proteins were labeled with
[35S]Cys-Met for 30 min at 7 h postinfection and
immunoprecipitated with anti-SeV serum ( SeV), anti-C serum ( C),
or anti-Vu serum ( Vu). The proteins were analyzed by SDS-PAGE and
processed for autoradiography. In a separate panel, infected cell
lysates were analyzed by Western blotting. The blotted membrane was
probed with anti-P serum as a primary antibody ( P). Mock, uninfected
cell lysates were used for immunoprecipitation; F0,
precursor of the F protein.
|
|
The anti-Vu antibody precipitated the V protein of SeV
V-C
341S, SeV V-C
365R, and SeV WT, but not that
of SeV V
C or SeV
V(

), as expected (Fig.
5). The
amounts of V protein were equivalent
between SeV V-Cys mutants and SeV
WT, suggesting that the mutated
V proteins were synthesized as
efficiently as the wild-type V
protein. V
C was
identified in Western blotting using infected
cell lysates and the
anti-P antibody (Fig.
5). In this Western
blot, SeV V-C
365R
appears to have a smaller amount of V protein.
However, this was
probably due to the different amounts loaded
on the gel, as judged by
the different amounts of P protein (Fig.
5).
The stability of the mutant V proteins was estimated by a 15-min pulse
label and 3-h chase, followed by immunoprecipitation
and SDS-PAGE.
There was no difference in the amounts of V protein
after a 3-h chase
among SeV V-C
341S, SeV V-C
365R, and SeV WT
(data
not shown), suggesting that the mutant V proteins were stable
in
mammalian cells in spite of the point
mutations.
Replication of SeV V-C341S and SeV V-C365R
in cultured cells.
In order to examine whether the introduced
mutations caused any change in virus replication in cell culture,
LLC-MK2 cells were infected with SeV V-C341S or
SeV V-C365R at an MOI of 0.01. SeV V(
) and SeV
V
C initially replicated a little faster than did the SeV
V-Cys mutants and SeV WT, but finally all of the viruses reached a
comparable level on day 5 after infection (Fig.
6). The relatively rapid replication of
SeV V(
) and SeV V
C in CV1 cells was previously
reported (14, 15), and the present study indicates that this
is also true for LLC-MK2 cells. SeV V-C341S and
SeV V-C365R, however, grew as well as SeV WT (Fig. 6); the
new mutants are closer to the wild-type virus in this respect. SeV
V-C341S and SeV V-C365R were similar to SeV WT
in plaque size and shape in CV1 cells (data not shown). Furthermore, all of the viruses displayed an identical replication pattern in
LLC-MK2 cells at an input MOI of 20 (data not shown). These results demonstrate that SeV V-C341S and SeV
V-C365R replicate similarly to the parent wild-type SeV in
cultured cells. Thus, mutations in cysteine residues did not apparently
have any detrimental effect on virus replication in cell culture.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 6.
Replication of SeV V mutants in cultured cells. Three
dishes of LLC-MK2 cells were infected with SeV
V-C341S, SeV V-C365R, SeV WT, SeV V( ), and
SeV V C at an MOI of 0.01, and a part of the culture
medium was taken daily. Mean HAU values (bars) and virus titers
(symbols and lines) are shown in the graph.
|
|
Pathogenicity and replication of SeV V-C341S and SeV
V-C365R in mice.
We next investigated the
pathogenicity of the mutant viruses to mice. In the infection
experiment, three to five 3-week-old ICR mice were infected in each
group. When 106 CIU of virus was inoculated into a mouse,
SeV WT killed four of the five mice, whereas SeV V-C341S
killed no mice and SeV V-C365R killed only one of the five
mice (Fig. 7). At 107
CIU/mouse, SeV WT killed all of the mice, whereas SeV
V-C341S killed only two of the five mice. SeV
V-C365R killed four of the five mice, but they survived
longer than with SeV WT (Fig. 7). Comparison of the 50% mouse lethal
dose (MLD50) demonstrated that SeV V-C341S
pathogenicity was only 3% of that of the wild-type virus and that SeV
V-C365R pathogenicity was 10% of the wild-type level
(Table 1), indicating that the virulence
of these mutants is attenuated in mice compared with the parent
wild-type virus. It is noteworthy that the MLD50 values for
SeV V-C341S and SeV V-C365R are close to that
of SeV V
C (Table 1). This shows that a single point
mutation at the conserved cysteine residues in the Vu domain abolished
the function of the entire Vu domain.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 7.
Body weight changes of mice infected with SeV V-Cys
mutants. Three to five mice were infected with 106 or
107 CIU of SeV V-C341S, SeV
V-C365R, or SeV WT per mouse, and the body weight of each
mouse was checked daily. Each dot indicates an individual mouse, and an
X marks the death of a mouse.
|
|
Virus replication in the mouse lung was then investigated in detail
(Fig.
8). When three mice in each group
were infected
with 10
7 CIU of wild-type or mutant virus per
mouse, all of the viruses
replicated equally to about 10
7
CIU per mouse lung on day 1. Virus replication then diverged:
wild-type
virus replicated further to reach a maximal level, which
was maintained
from days 2 to 5, while in contrast, the virus
titer of SeV V(

)
rapidly decreased from day 2 (Fig.
8) (
14).
Replication of
SeV V
C was very similar to that of SeV V(

),
but SeV
V
C grew more efficiently than SeV V(

) (Fig.
8)
(
15).
The difference between SeV WT and SeV
V
C was far more obvious
than that between SeV
V
C and SeV V(

). This suggests that
the Vu domain is
mainly involved in virus replication in mice,
although the P/V common
region also has some involvement. In SeV
V-C
341S and SeV
V-C
365R infection, virus replication was almost
the same as
that of SeV V
C, and this is consistent with the
MLD
50 values of these viruses. An exception was that,
unlike SeV
V
C, the virus titers of SeV
V-C
341S and SeV V-C
365R slightly
increased
rather than decreased around day 5, which was somewhat
similar to SeV
WT (Fig.
8).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 8.
Replication of SeV V mutants in the mouse lung. Mice
were infected with 107 CIU of SeV V-C341S, SeV
V-C365R, SeV V( ), SeV V C, and SeV WT per
mouse, and three mice for each virus were sacrificed on days 0, 1, 2, 3, 5, 7, and 9. The lungs were removed from each mouse, homogenized in
1 ml of MEM, and infectivity was measured. Each point represents the
mean infectivity in three mice, and bars indicate the standard
deviation. One mouse each infected with SeV WT and SeV
V-C365R died on day 8, and the lungs were removed on that
day.
|
|
 |
DISCUSSION |
In this work, we demonstrated that the Vu domain of SeV was
capable of binding zinc ions. Similar findings have also been reported
for SV5, measles virus, and Newcastle disease virus (21, 25,
29). In the case of SV5, it was found, by using inductively coupled argon plasma atomic emission spectroscopy, that each molecule of the V protein binds two atoms of zinc (25). The
zinc-binding assay employed in our study did not allow a quantitative
analysis of the molar ratio of zinc ions per molecule of V protein.
However, GST-Vu showed a strong zinc-binding signal, 7.2-fold greater
than that of GST, indicating its potential zinc-binding capacity.
Generally, both cysteine and histidine residues can mediate zinc
binding. For example, two histidine residues and two cysteine residues can bind one zinc atom in the C2H2 zinc finger structure. In order to
test whether the zinc-binding activity of the Vu domain is cysteine
dependent, we performed the assay under reducing conditions that
specifically allowed the detection of zinc binding through cysteine
residues (2). It was observed that the GST-Vu fusion protein
definitely required reducing conditions to bind zinc (data not shown),
indicating that coordination of the metal atoms could be mediated by
cysteine residues. In contrast, carbonic anhydrase, a
well-characterized zinc-binding metalloprotein which binds one zinc
atom through three histidine residues, was used as a control protein
and bound only a trace amount of zinc ions (Fig. 4B). Furthermore,
mutations in cysteine residues considerably reduced zinc-binding
activity, suggesting that zinc binding of the Vu domain is dependent on
these conserved cysteine residues. The impairment of zinc binding may
be related to the distinct conformation, as indicated by partial
protease susceptibilities of the mutant GST-Vu proteins in E. coli. Given the reducing environment in the cytosol of eukaryotic
cells and the presence of zinc, we predict that the V protein would
bind zinc in vivo.
Although the V proteins of SeV and other paramyxoviruses were shown to
bind zinc, the biological significance of the zinc binding was still an
enigma. The present study using cysteine mutant viruses provided
evidence supporting the notion that the zinc-binding capacity is
involved in viral pathogenesis in vivo. Two mutant viruses, SeV
V-C341S and SeV V-C365R, which represent the
maximal and minimal zinc-binding capacity of corresponding fusion
proteins, respectively, were constructed with a reverse genetics
system. Like SeV V(
) and SeV V
C, these cysteine mutant
viruses exhibited a change in neither major viral protein synthesis nor
replication in cultured cells. There was also no observable difference
in stability of the mutant V proteins compared with that of the
wild-type V protein in cultured cells. On the contrary, the virulence
of these two mutants was attenuated remarkably in mice. The
MLD50 values of SeV V-C341S and SeV
V-C365R indicated that the mutants were only 3 and 10% as
pathogenic as the wild-type parent SeV, respectively, and nearly as
pathogenic as SeV V
C. This attenuation was also observed
in studies on viral replication in the mouse lung and mouse body weight
changes. These results clearly indicate that even a single mutation in
the highly conserved cysteine residues in the Vu domain could disrupt
the function of the entire Vu domain.
The growth patterns of two cysteine mutant viruses in the mouse lung
were very similar but not identical to that of SeV V
C. On day 5 postinfection, the titers of V cysteine mutants appeared to
increase slightly, as with wild-type SeV (Fig. 8). This is possible
because SeV V-C341S and SeV V-C365R are
single-amino-acid-substituted viruses, whereas SeV V(
) and SeV
V
C have deletions in the Vu domain. As a result, the V
protein function of the cysteine mutants might not be entirely
abolished, making the viruses somewhat resistant to host antiviral
response. After day 5, specific cellular immunity participated in the
antivirus response, and the viruses were cleared thereafter (Fig. 8).
One unexpected result was that although GST-Vu-C341S could
bind more zinc ions (68% of the wild-type level) than
GST-V-C365R (22% of the wild-type level), SeV
V-C341S appeared to be less virulent than SeV
V-C365R in vivo. This discrepancy implies that zinc-binding
capacity and virulence in mice are not strongly correlated. It can be
considered that zinc binding is a correct but incomplete marker of the
proper conformation and function of the V protein. In such a scenario,
although Cys341 is less important for zinc binding than the
other cysteine residues, it may be critical for structure formation or
function of the V protein by an as yet unknown mechanism.
It seems that the highly conserved cysteine residues are involved both
in the zinc-binding capacity of the Vu domain and in viral pathogenesis
in vivo. Although some enzymes utilize zinc in their active centers,
most zinc-binding proteins can form a stable structural element within
the protein itself through zinc binding. This structure could
participate in protein-protein and protein-nucleic acid interactions.
The results of early studies suggest that zinc fingers mediate nucleic
acid binding in transcription factors (3) and
homodimerization of proteins (10). More recent studies have
revealed that many zinc fingers can mediate protein-protein interaction
(22). It is possible that the V protein can also adopt a
particular conformation in its unique carboxyl terminus through zinc
binding and subsequently interacted with host cell protein(s) in vivo.
A recent study showed that the V protein of SV5 interacts via the
conserved cysteine residues with a 127-kDa subunit (DDB1) of the
damage-specific DNA-binding protein (DDB), a host factor controlling
cell cycle progression (20). However, it was also
demonstrated in this study that the SeV V protein does not interact
with DDB1. We assume that the SeV V protein may instead interact with
another host factor(s) and may play an important role in facilitating
virus multiplication by modifying early host immunity through
interaction. The validity of this hypothesis remains to be clarified in
a future study.
In conclusion, our study showed that the conserved cysteine residues in
the SeV V protein are important for its zinc-binding capacity and for
virus pathogenicity in mice. A function of the V protein, which is
probably related to circumvention of innate host immunity, is thought
to be mediated through its cysteine cluster in the carboxyl terminus. A
possible host partner of the SeV V protein should be investigated to
understand the biological activity of the V protein.
 |
ACKNOWLEDGMENTS |
We thank the Research Center for Molecular Medicine, Hiroshima
University School of Medicine, for the use of their facilities.
This study was supported in part by the Japan-China Sasakawa Medical
Fellowship awarded to C. Huang.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Bacteriology, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Phone: 81-82-257-5157. Fax: 81-82-257-5159. E-mail:
takemasa{at}mcai.med.hiroshima-u.ac.jp.
Present address: Department of Viral Diseases and Vaccine Control,
National Institute of Infectious Diseases, Musashi-Murayama 208-0011, Japan.
Present address: AIDS Research Center, National Institute of
Infectious Diseases, Tokyo 162-8640, Japan.
 |
REFERENCES |
| 1.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl (ed.).
1998.
Current protocols in molecular biology.
John Wiley & Sons, Inc., New York, N.Y.
|
| 2.
|
Barbosa, M. S.,
D. R. Lowy, and J. T. Schiller.
1989.
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins.
J. Virol.
63:1404-1407[Abstract/Free Full Text].
|
| 3.
|
Berg, J. M.
1986.
Potential metal-binding domains in nucleic acid binding proteins.
Science
232:485-487[Abstract/Free Full Text].
|
| 4.
|
Curran, J.
1998.
A role for the Sendai virus P protein trimer in RNA synthesis.
J. Virol.
72:4274-4280[Abstract/Free Full Text].
|
| 5.
|
Curran, J.,
M. de Melo,
S. Moyer, and D. Kolakofsky.
1991.
Characterization of the Sendai virus V protein with an anti-peptide antiserum.
Virology
184:108-116[CrossRef][Medline].
|
| 6.
|
Curran, J.,
J. B. Marq, and D. Kolakofsky.
1995.
An N-terminal domain of the Sendai paramyxovirus P protein acts as a chaperone for the NP protein during the nascent chain assembly step of genome replication.
J. Virol.
69:849-855[Abstract].
|
| 7.
|
Curran, J.,
J. B. Marq, and D. Kolakofsky.
1992.
The Sendai virus nonstructural C proteins specifically inhibit viral mRNA synthesis.
Virology
189:647-656[CrossRef][Medline].
|
| 8.
|
Delenda, C.,
S. Hausmann,
D. Garcin, and D. Kolakofsky.
1997.
Normal cellular replication of Sendai virus without the trans-frame, nonstructural V protein.
Virology
228:55-62[CrossRef][Medline].
|
| 9.
|
Delenda, C.,
G. Taylor,
S. Hausmann,
D. Garcin, and D. Kolakofsky.
1998.
Sendai viruses with altered P, V, and W protein expression.
Virology
242:327-337[CrossRef][Medline].
|
| 10.
|
Frankel, A. D.,
D. S. Bredt, and C. O. Pabo.
1988.
Tat protein from human immunodeficiency virus forms a metal-linked dimer.
Science
240:70-73[Abstract/Free Full Text].
|
| 11.
|
Garcin, D.,
P. Latorre, and D. Kolakofsky.
1999.
Sendai virus C proteins counteract the interferon-mediated induction of an antiviral state.
J. Virol.
73:6559-6565[Abstract/Free Full Text].
|
| 12.
|
Gotoh, B.,
K. Takeuchi,
T. Komatsu,
J. Yokoo,
Y. Kimura,
A. Kurotani,
A. Kato, and Y. Nagai.
1999.
Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses.
FEBS Lett.
459:205-210[CrossRef][Medline].
|
| 13.
|
Horikami, S. M.,
J. Curran,
D. Kolakofsky, and S. A. Moyer.
1992.
Complexes of Sendai virus NP-P and P-L proteins are required for defective interfering particle genome replication in vitro.
J. Virol.
66:4901-4908[Abstract/Free Full Text].
|
| 14.
|
Kato, A.,
K. Kiyotani,
Y. Sakai,
T. Yoshida, and Y. Nagai.
1997.
The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis.
EMBO J.
16:578-587[CrossRef][Medline].
|
| 15.
|
Kato, A.,
K. Kiyotani,
Y. Sakai,
T. Yoshida,
T. Shioda, and Y. Nagai.
1997.
Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis.
J. Virol.
71:7266-7272[Abstract].
|
| 16.
|
Kato, A.,
Y. Sakai,
T. Shioda,
T. Kondo,
M. Nakanishi, and Y. Nagai.
1996.
Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense.
Genes Cells
1:569-579[Abstract].
|
| 17.
|
Kiyotani, K.,
S. Takao,
T. Sakaguchi, and T. Yoshida.
1990.
Immediate protection of mice from lethal wild-type Sendai virus (HVJ) infections by a temperature-sensitive mutant, HVJpi, possessing homologous interfering capacity.
Virology
177:65-74[CrossRef][Medline].
|
| 18.
|
Kurotani, A.,
K. Kiyotani,
A. Kato,
T. Shioda,
Y. Sakai,
K. Mizumoto,
T. Yoshida, and Y. Nagai.
1998.
Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis.
Genes Cells
3:111-124[Abstract].
|
| 19.
|
Lamb, R. A., and D. Kolakofsky.
1996.
Paramyxoviridae: the viruses and their replication, p. 1177-1204.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Raven Press, New York, N.Y.
|
| 20.
|
Lin, G. Y.,
R. G. Paterson,
C. D. Richardson, and R. A. Lamb.
1998.
The V protein of the paramyxovirus SV5 interacts with damage-specific DNA binding protein.
Virology
249:189-200[CrossRef][Medline].
|
| 21.
|
Liston, P., and D. J. Briedis.
1994.
Measles virus V protein binds zinc.
Virology
198:399-404[CrossRef][Medline].
|
| 22.
|
Mackay, J. P., and M. Crossley.
1998.
Zinc fingers are sticking together.
Trends Biochem. Sci.
23:1-4[CrossRef][Medline].
|
| 23.
|
Nagai, Y.
1999.
Paramyxovirus replication and pathogenesis: reverse genetics transforms understanding.
Rev. Med. Virol.
9:83-99[CrossRef][Medline].
|
| 24.
|
Nagai, Y., and A. Kato.
1999.
Paramyxovirus reverse genetics is coming of age.
Microbiol. Immunol.
43:613-624[Medline].
|
| 25.
|
Paterson, R. G.,
G. P. Leser,
M. A. Shaughnessy, and R. A. Lamb.
1995.
The paramyxovirus SV5 V protein binds two atoms of zinc and is a structural component of virions.
Virology
208:121-131[CrossRef][Medline].
|
| 26.
|
Sakaguchi, T.,
K. Kiyotani,
A. Kato,
M. Asakawa,
Y. Fujii,
Y. Nagai, and T. Yoshida.
1997.
Phosphorylation of the Sendai virus M protein is not essential for virus replication either in vitro or in vivo.
Virology
235:360-366[CrossRef][Medline].
|
| 27.
|
Sakaguchi, T.,
G. P. Leser, and R. A. Lamb.
1996.
The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus.
J. Cell Biol.
133:733-747[Abstract/Free Full Text].
|
| 28.
|
Sakaguchi, T.,
T. Uchiyama,
Y. Fujii,
K. Kiyotani,
A. Kato,
Y. Nagai,
A. Kawai, and T. Yoshida.
1999.
Double-layered membrane vesicles released from mammalian cells infected with Sendai virus expressing the matrix protein of vesicular stomatitis virus.
Virology
263:230-243[CrossRef][Medline].
|
| 29.
|
Steward, M.,
A. C. Samson,
W. Errington, and P. T. Emmerson.
1995.
The Newcastle disease virus V protein binds zinc.
Arch. Virol.
140:1321-1328[CrossRef][Medline].
|
| 30.
|
Thomas, S. M.,
R. A. Lamb, and R. G. Paterson.
1988.
Two mRNAs that differ by two nontemplated nucleotides encode the amino coterminal proteins P and V of the paramyxovirus SV5.
Cell
54:891-902[CrossRef][Medline].
|
| 31.
|
Vidal, S.,
J. Curran, and D. Kolakofsky.
1990.
Editing of the Sendai virus P/C mRNA by G insertion occurs during mRNA synthesis via a virus-encoded activity.
J. Virol.
64:239-246[Abstract/Free Full Text].
|
Journal of Virology, September 2000, p. 7834-7841, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kato, A., Kiyotani, K., Kubota, T., Yoshida, T., Tashiro, M., Nagai, Y.
(2007). Importance of the Anti-Interferon Capacity of Sendai Virus C Protein for Pathogenicity in Mice. J. Virol.
81: 3264-3271
[Abstract]
[Full Text]
-
Mehle, A., Thomas, E. R., Rajendran, K. S., Gabuzda, D.
(2006). A Zinc-binding Region in Vif Binds Cul5 and Determines Cullin Selection. J. Biol. Chem.
281: 17259-17265
[Abstract]
[Full Text]
-
Hui, E. K.-W., Smee, D. F., Wong, M.-H., Nayak, D. P.
(2006). Mutations in Influenza Virus M1 CCHH, the Putative Zinc Finger Motif, Cause Attenuation in Mice and Protect Mice against Lethal Influenza Virus Infection.. J. Virol.
80: 5697-5707
[Abstract]
[Full Text]
-
Kato, A., Cortese-Grogan, C., Moyer, S. A., Sugahara, F., Sakaguchi, T., Kubota, T., Otsuki, N., Kohase, M., Tashiro, M., Nagai, Y.
(2004). Characterization of the Amino Acid Residues of Sendai Virus C Protein That Are Critically Involved in Its Interferon Antagonism and RNA Synthesis Down-Regulation. J. Virol.
78: 7443-7454
[Abstract]
[Full Text]
-
Huang, Z., Krishnamurthy, S., Panda, A., Samal, S. K.
(2003). Newcastle Disease Virus V Protein Is Associated with Viral Pathogenesis and Functions as an Alpha Interferon Antagonist. J. Virol.
77: 8676-8685
[Abstract]
[Full Text]
-
Modrof, J., Becker, S., Muhlberger, E.
(2003). Ebola Virus Transcription Activator VP30 Is a Zinc-Binding Protein. J. Virol.
77: 3334-3338
[Abstract]
[Full Text]
-
Park, M.-S., Shaw, M. L., Munoz-Jordan, J., Cros, J. F., Nakaya, T., Bouvier, N., Palese, P., Garcia-Sastre, A., Basler, C. F.
(2002). Newcastle Disease Virus (NDV)-Based Assay Demonstrates Interferon-Antagonist Activity for the NDV V Protein and the Nipah Virus V, W, and C Proteins. J. Virol.
77: 1501-1511
[Abstract]
[Full Text]
-
Yokosawa, N., Yokota, S.-i., Kubota, T., Fujii, N.
(2002). C-Terminal Region of STAT-1{alpha} Is Not Necessary for Its Ubiquitination and Degradation Caused by Mumps Virus V Protein. J. Virol.
76: 12683-12690
[Abstract]
[Full Text]
-
Neumann, G., Whitt, M. A., Kawaoka, Y.
(2002). A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J. Gen. Virol.
83: 2635-2662
[Abstract]
[Full Text]
-
Kato, A., Ohnishi, Y., Hishiyama, M., Kohase, M., Saito, S., Tashiro, M., Nagai, Y.
(2002). The Amino-Terminal Half of Sendai Virus C Protein Is Not Responsible for either Counteracting the Antiviral Action of Interferons or Down-Regulating Viral RNA Synthesis. J. Virol.
76: 7114-7124
[Abstract]
[Full Text]
-
Sakaguchi, T., Uchiyama, T., Huang, C., Fukuhara, N., Kiyotani, K., Nagai, Y., Yoshida, T.
(2002). Alteration of Sendai Virus Morphogenesis and Nucleocapsid Incorporation due to Mutation of Cysteine Residues of the Matrix Protein. J. Virol.
76: 1682-1690
[Abstract]
[Full Text]
-
Kato, A., Ohnishi, Y., Kohase, M., Saito, S., Tashiro, M., Nagai, Y.
(2001). Y2, the Smallest of the Sendai Virus C Proteins, Is Fully Capable of both Counteracting the Antiviral Action of Interferons and Inhibiting Viral RNA Synthesis. J. Virol.
75: 3802-3810
[Abstract]
[Full Text]
-
Parks, C. L., Lerch, R. A., Walpita, P., Wang, H.-P., Sidhu, M. S., Udem, S. A.
(2001). Comparison of Predicted Amino Acid Sequences of Measles Virus Strains in the Edmonston Vaccine Lineage. J. Virol.
75: 910-920
[Abstract]
[Full Text]